Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy.
Ge QinFan BaiHuabin HuJianwei ZhangWeixiang ZhanZehua WuJianxia LiYang FuYan-Hong DengPublished in: Molecular medicine (Cambridge, Mass.) (2024)
This study suggests that the NAT10/NPM1 axis is a promising therapeutic target in malignant tumors.